Answers are grounded in this paper and cite their sources.
Retrospective cohort study evaluates CAR-T therapy outcomes, emphasizing sociodemographic disparities in patients.
e23435 Background: Chimeric Antigen Receptor T-cell (CAR-T) therapy is an effective treatment for relapsed/refractory hematologic malignancies. However, disparities in access, toxicity burden, and outcomes may exist for patients from minoritized and underserved backgrounds. This study evaluated real-world CAR-T therapy outcomes at a single academic cancer center, focusing on socioeconomic and demographic predictors of treatment response and toxicity. Methods: We performed a retrospective cohort study of 101 adult patients who received commercial CAR-T therapy (axicabtagene ciloleucel, brexucabtagene autoleucel, ciltacabtagene autoleucel) at USC Norris Comprehensive Cancer Center between 2022–2025. Demographic, geographic, clinical, and treatment-related variables were extracted from REDCap. Multivariable logistic regression and chi-square/Fisher’s exact tests were used to assess associations between sociodemographic variables—including race/ethnicity, insurance status, Social Vulnerability Index (SVI), and distance from the transplant center—and key outcomes: treatment response, toxicity (CRS/ICANS), ICU admission, and delays to infusion. Results: The cohort had a median age of 62 years; 63% were male and 38% identified as Hispanic. Diffuse Large B-Cell Lymphoma (DLBCL) (44%) was the most common diagnosis, followed by Multiple Myeloma (22%) and Acute Lymphoblastic Leukemia (ALL) (21%). Insurance coverage included commercial (49%), Medicare (27%), and Medicaid (23%). In multivariable analyses, female sex was significantly associated with lower odds of achieving a treatment response compared to males (OR 6.69 for males, p = 0.038). Public insurance (Medicare or Medicaid) was associated with increased risk of severe neurotoxicity (ICANS grade ≥3, p = 0.012) and ICU admission ( p = 0.035). DLBCL diagnosis was significantly associated with reduced odds of response ( p < 0.05), highlighting disease-specific variation in CAR-T efficacy. No statistically significant associations were found between outcomes and SVI, race/ethnicity, or distance to the transplant center. Time from referral to infusion also did not significantly differ by ethnicity, insurance type, or SVI quartile. Conclusions: In this single-center cohort, female patients and those with DLBCL had significantly lower odds of response to CAR-T therapy. Public insurance was associated with higher neurotoxicity and ICU utilization. These findings underscore potential disparities in CAR-T outcomes based on sex, insurance status, and disease subtype, even within an academic setting. Larger, multi-center studies are warranted to confirm these associations and inform equity-focused strategies in cellular therapy delivery.
No takes yet. Share an insight, caveat, or question.
Orozco et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: